Clinical

Macitentan reduces risk of mortality in PAH patients, study finds

LAVAL, Que. | Actelion Pharmaceuticals Canada has announced that a pivotal study with macitentan in patients with pulmonary arterial hypertension (PAH) has demonstrated a significant reduction in morbidity and mortality.
Insoles offer no relief
Psychiatry in the News - September 20, 2013
Integrase inhibitor best for HIV patients with cancer

A third of deaths in HIV patients now due to malignancy: Texas study
Three of 10 new antimicrobials have unrecognized side-effects

Package inserts have incomplete safety information, researchers find
Major depression in HIV patients linked with viral escape into cerebrospinal fluid

Ongoing CSF viral replication may be more common than previously thought: U.S. researchers
Renal function assessment lacking before starting metformin in diabetes patients

A serum creatinine measurement is not performed in about one-quarter of diabetes patients prior to starting metformin therapy, according to the results of a new Canadian study.
Are you doing enough for patients at risk of suicide?

Drug cuts morbidity in pulmonary arterial hypertension